The role of renin–angiotensin system in the chronic allograft nephropathy: an immunohistochemical study

References

• Paul LC. Chronic allograft nephropathy: An update. Kidney Intern. 1999;56:783–793
   PubMed Web of Science ®Google Scholar
• Joosten SA, Sijpkens WJ, Kooten CV, Paul LC. Rejeição crônica ao aloenxerto renal: Considerações fisiopatológicas. Kidney Intern. 2005;1:119–130
   Google Scholar
• Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol. 2000;20(2):126–147
   PubMed Web of Science ®Google Scholar
• Waller JR, Nicholson ML. Molecular mechanisms of renal allograft fibrosis. Brit J Surg. 2001;88:1429–1441
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Egido J. Inflammation and angiotensin II. Intern J Biochem Cell Biol. 2003;35:881–900
   PubMed Web of Science ®Google Scholar
• Wolf G. Lesão renal devido à ativação do sistema renina-angiotensina-aldosterona pela via do fator de crescimento transformador b. Kidney Intern. 2007;2:129–133
   Google Scholar
• Geara AS, Azzi J, Jurewicz M, Abdi R. The renin–angiotensin system: An old, newly discovered player in immunoregulation. Transplant Rev. 2009;23:151–158
   Google Scholar
• Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-b-1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001;16(Suppl 1):114–116
   PubMedGoogle Scholar
• Shang M-H, Yuan W-J, Zhang S-J, Fan Y, Zhang Z. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity. Chin Med J. 2008;121(11):983–988
   PubMed Web of Science ®Google Scholar
• Montanaro D, Gropuzzo M, Tulissi P, et al. Renoprotective effect of early inhibition of the renin–angiotensin system in renal transplant recipients. Transplant Proc. 2005;37:991–993
   PubMed Web of Science ®Google Scholar
• Artz MA, Hilbrands LB, Borm G, Assmann KJM, Wetzels JFM. Blockade of the renin–angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant. 2004;19:2852–2857
   PubMed Web of Science ®Google Scholar
• Zaltzman JS, Nash N, Chiu R, Prasad GVR. Renin–angiotensin system blockade in biopsy-proven allograft nephropathy. Transplant Proc. 2003;35:2415–2417
   PubMed Web of Science ®Google Scholar
• Oka K, Moriyama T, Takahara S, et al. Increased expression of renin in chronic allograft nephropathy. Transplant Proc. 2005;37:2131–2134
   PubMed Web of Science ®Google Scholar
• Becker BN, Jacobson LM, Hullett DA, et al. Type 2 angiotensin receptor expression in human renal allografts: An association with chronic allograft nephropathy. Clin Nephrol. 2002;57:19–26
   PubMed Web of Science ®Google Scholar
• Mas V, Alvarellos T, Giraudo C, Massari P, Boccardo G. Intragraft messenger RNA expression of angiotensinogen: Relationship with transforming growth factor beta-1 and chronic allograft nephropathy in kidney transplant patients. Transplantation. 2002;74(5):718–721
   PubMed Web of Science ®Google Scholar
• Mas V, Maluf D, Archer K, et al. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation. 2007;83:448–457
   PubMed Web of Science ®Google Scholar
• Racusen LC, Solez K, Colvin RB, et al. The Banff working classification of renal allograft pathology. Kidney Intern. 1999;55:713–723
   PubMed Web of Science ®Google Scholar
• Zar JH. Biostatistical Analysis. New Jersey, USA: Prentice-Hall; 1999
   Google Scholar
• Solez K, Colvin RB, Racusen LC, et al. Banff'05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (“CAN”). Am J Transplant. 2007;7:518–526
   PubMed Web of Science ®Google Scholar
• Arias M, Séron D, Moreso F, Bestard O, Praga M. Chronic renal allograft damage: Existing challenges. Transplantation. 2011;91(9S):S4–S25
   Google Scholar
• Nankivel BJ, Borrows RJ, Fung CLS, O'Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. New Eng J Med. 2003;349:2326–2333
   PubMedGoogle Scholar
• Moscoso-Solorzano GT, Mastroiani-Kirsztajn G, Ozaki KS, Franco MF, Pacheco-Silva A, Câmara NOS. Synergistic effect of mycophenolate mofetil and angiotensin-converting enzyme inhibitor in patients with chronic allograft nephropathy. Brazil J Med Biol Res. 2009;42:445–452
   PubMed Web of Science ®Google Scholar
• Noris M, Mister M, Pezzotta A, et al. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Intern. 2003;64:2253–2261
   PubMed Web of Science ®Google Scholar
• Smit-van Oosten A, Henning RH, Goor HV. Strain differences in angiotensin-converting enzyme and angiotensin II type I receptor expression. Possible implications for experimental chronic renal transplant failure. J RAAS. 2002;3(1):46–53
   Google Scholar
• Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Intern. 2000;57:982–991
   PubMed Web of Science ®Google Scholar
• Ziai F, Nagano H, Kusaka M, et al. Renal allograft protection with losartan in Fisher → Lewis rats: Hemodynamics, macrophages, and cytokines. Kidney Intern. 2000;57:2618–2625
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Interactions of transforming growth factor-b and angiotensin II in renal fibrosis. Hypertension. 1998;31(Part 2):181–188
   PubMedGoogle Scholar
• Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11(6):RA194–RA205
   PubMed Web of Science ®Google Scholar
• Harris S, Coupes BM, Roberts SA, Roberts IS, Short CD, Brenchley PE. TGFβ1 in chronic allograft nephropathy following renal transplantation. J Nephrol. 2007;20(2):177–185
   PubMed Web of Science ®Google Scholar
• Seron D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Intern. 1997;51:310–316
   PubMed Web of Science ®Google Scholar
• Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation: Insights into patient management and pathogenesis. Am J Transplant. 2007;7:512–517
   PubMed Web of Science ®Google Scholar
• Mengel M, Gwinner W, Schwarz A, et al. Infiltrates in protocols biopsies from renal allografts. Am J Transplant. 2007;7:356–365
   PubMed Web of Science ®Google Scholar
• Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Tranplant. 2006;6:747–752
   PubMed Web of Science ®Google Scholar
• Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol. 2003;14:1046–1052
   PubMed Web of Science ®Google Scholar
• Divella C, Rossini M, Loverre A, et al. Immunohistochemical characterization of glomerular and tubulointerstitial infiltrates in renal transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant. 2010;25:4071–4077
   PubMed Web of Science ®Google Scholar
• Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol. 2005;16:3015–3026
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Progression of renal damage in chronic rejection. Kidney Intern. 2000;57(Suppl. 75):S62–S70
   Google Scholar
• Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant. 2008;8:753–760
   PubMed Web of Science ®Google Scholar